Search the Newsreel

BioMarin earnings on deck as flagship drug faces competition

BioMarin Pharmaceutical Inc. is set to report second-quarter earnings, with analysts expecting 95 cents per share on $939.2 million in revenue, an increase from the previous quarter. The upcoming earnings call will likely focus on the competitive landscape for its top drug, VOXZOGO, which …

BioMarin Pharmaceutical Q2 Earnings Call Highlights

BioMarin Pharmaceutical's Q2 revenue approached $1 billion, a 20% increase year-over-year, driven by its rare-disease portfolio and the Amicus acquisition. The company raised its full-year guidance for revenue, VOXZOGO revenue, and non-GAAP EPS, projecting significant growth from Amicus therapies and VOXZOGO becoming a $1 …

BioMarin Pharmaceutical Inc (BMRN) Gewinnprognose: Zukünftige EPS & Umsatzwachstumsprognosen

BioMarin Pharmaceutical (NASDAQ:BMRN) Releases Quarterly Earnings Results

BioMarin Pharmaceutical (BMRN) To Report Earnings Tomorrow: Here Is What To Expect

Molecule to Market: Agentifying the Pharma Value Chain

This article details an upcoming webinar titled "Molecule to Market: Agentifying the Pharma Value Chain" which will discuss how to overcome challenges in the pharmaceutical value chain by building an Enterprise AI Foundry for unified, AI-ready data. Speakers from BioMarin Pharmaceutical, Databricks, and Tredence …

BioMarin Pharmaceutical Number of Employees 2026 | Employee Count & Headcount Data

This article provides an in-depth analysis of BioMarin Pharmaceutical's workforce data as of March 2026, sourced from Revelio Labs. It details the company's employee count (3,249), its 1.5% decline since 2023, and its active hiring with 363 job postings. The report also covers employee …

BioMarin to Host Second Quarter 2026 Financial Results Conference Call and Webcast on Thursday, August 6, 2026, at 4:30pm ET

BioMarin Pharmaceutical Inc. will host a conference call and webcast on Thursday, August 6, 2026, at 4:30 p.m. ET to discuss its second-quarter 2026 financial results and provide a business update. Alexander Hardy, President and CEO, will lead the call. Interested parties can access …

BioMarin CEO to Give Business Update in Aug. 6 Webcast

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced that its President and CEO, Alexander Hardy, will host a conference call and webcast on Thursday, August 6, 2026, at 4:30 p.m. ET. The event will cover the company's second-quarter 2026 financial results and provide a general business …

BioMarin Pharmaceutical Inc (BMRN) Financial Health: Profitability & Balance Sheet Analysis

BioMarin Pharmaceutical Inc (BMRN) currently holds a robust financial score of 9.27, ranking 4th out of 155 in the Pharmaceuticals industry, indicating high operating efficiency. The company recently reported a 2.83% year-over-year increase in quarterly revenue, reaching $766.21 million, and a significant 43.17% rise …

H.C. Wainwright reiterates BioMarin stock rating at Neutral

H.C. Wainwright has reiterated a Neutral rating and $50.00 price target for BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), despite the stock trading above this target and InvestingPro suggesting it is undervalued. The firm's renewed stance comes after the FDA published draft guidance describing a generic pathway …

BioMarin Pharmaceutical Inc. Revenue Breakdown – NASDAQ:BMRN

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) generated $3.22 billion USD in revenue last year, primarily from its Innovative Therapies segment. This marks an increase from $2.85 billion USD in the previous year for the same segment. The United States was the largest geographical contributor, accounting …

Does BioMarin (BMRN) Expanding Into ReNU Syndrome Refine Its Rare Disease Pipeline Strategy?

BioMarin Pharmaceutical's collaboration with n-Lorem Foundation to develop an antisense oligonucleotide therapy for ReNU syndrome aligns with its strategy of focusing on high unmet-need rare diseases. While this early-stage program supports BioMarin's long-term pipeline, the near-term investment narrative remains dominated by VOXZOGO regulatory milestones …

How (BMRN) Movements Inform Risk Allocation Models

This article analyzes Biomarin Pharmaceutical Inc. (NASDAQ: BMRN) providing AI-generated insights for risk allocation models. It highlights strong near-term sentiment but neutral mid and long-term outlooks, with no clear price positioning signal or resistance levels above the current price. The analysis includes specific institutional …

BioMarin and n-Lorem Foundation Enter Research Collaboration for ReNU Syndrome Treatment

BioMarin Pharmaceutical Inc. and n-Lorem Foundation have announced a partnership and global exclusive license agreement to develop the first antisense oligonucleotide (ASO) medicine for ReNU syndrome, a neurodevelopmental disorder identified in 2024. The collaboration focuses on an ASO candidate targeting the RNU4-2 (n.64_65insT) variant, …

BioMarin partners with n-Lorem to develop ReNU syndrome treatment

BioMarin Pharmaceutical Inc. and the n-Lorem Foundation have announced a strategic collaboration and exclusive license agreement to develop an antisense oligonucleotide (ASO) medicine for ReNU syndrome. This rare neurodevelopmental genetic condition, discovered in 2024, is associated with cognitive, language, and adaptive behavioral impairments. The …

Analysts Estimate BioMarin Pharmaceutical (BMRN) to Report a Decline in Earnings: What to Look Out for

Analysts expect BioMarin Pharmaceutical (BMRN) to report a year-over-year decline in earnings but an increase in revenues for the quarter ended June 2026. With a Zacks Earnings ESP of -8.61% and a Zacks Rank #3, it is difficult to conclusively predict an earnings beat …

BioMarin Pharmaceutical (BMRN) to Post Quarterly Earnings on Monday

Biomarin Pharmaceutical Inc. (BMRN) Q2 2025 Earnings Report - Results, Call & Slides

BioMarin Pharmaceutical (BMRN) reported strong Q2 2025 earnings, beating analyst expectations for both EPS and revenue. The company recorded an actual EPS of $1.23 against a consensus of $0.86, and actual revenue of $827.47 million, surpassing the expected $761.95 million. This represents a significant …

BMRN|BioMarin Pharmaceutical Inc|Price:59.350|Chg%:+0.480

BioMarin Pharmaceutical Inc. (BMRN) shows strong fundamentals and high growth potential, with its stock trading within a range, making it suitable for swing trading. The company's valuation is considered fair, and multiple analysts rate it as a "Buy" with a target price indicating significant …

BioMarin Pharmaceutical Inc (BMRN) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of BioMarin Pharmaceutical Inc (BMRN), focusing on support and resistance levels, various technical indicators, and moving averages. It highlights that BMRN's stock is currently suitable for range-bound swing trading, with its price momentum ranking 151 out of 155 …

BioMarin Pharmaceutical (BMRN) On FDA Acceptance For VOXZOGO And The Valuation Case

BioMarin Pharmaceutical's stock is gaining attention after the FDA accepted its supplemental New Drug Application for VOXZOGO, indicating potential full approval. Although the stock has seen a 10.7% return over 90 days, its one-year performance has been weaker, suggesting mixed sentiment. Despite trading at …

BMRN|BioMarin Pharmaceutical Inc|Price:59.274|

BioMarin Pharmaceutical Inc (BMRN) has a "very healthy" fundamental outlook and high growth potential, with its valuation considered fairly valued within the Pharmaceuticals industry. Analysts have rated it as a "Buy" with a significant upside potential. The company shows strong fundamentals despite average recent …

BioMarin Pharmaceutical Inc. (BMRN) Stock Forecasts

BioMarin Pharmaceutical Inc. (BMRN) is a global biotechnology company specializing in therapies for rare genetic diseases. An Argus report from July 22, 2026, provides analysis on BMRN, though full details require an upgrade to premium research. The article also lists other related analyst reports …

BioMarin stock trades steady as rare disease revenue grows and gene therapy outlook develops

BioMarin Pharmaceutical Inc. (BMRN) stock remains steady as the company demonstrates growth in its rare disease revenue while actively developing gene therapy assets. The biotech firm's strategy involves substantial R&D investments in gene therapy programs, particularly for hemophilia A, prioritizing pipeline depth over short-term …

BMRN5187965 Bond Profile — Key Metrics

This article provides a detailed profile of the BioMarin Pharmaceutical Inc. 1.25% 15-MAY-2027 bond (BMRN5187965 FINRA). It lists key metrics such as issuer, issue date, maturity date, outstanding amount, face value, minimum denomination, and coupon rate. The profile also includes a brief description of …

BioMarin (BMRN) Wins FDA Review For VOXZOGO Full Approval In Achondroplasia

BioMarin Pharmaceutical (BMRN) has received FDA acceptance for its supplemental New Drug Application for VOXZOGO, aiming for full approval of the treatment for children with achondroplasia. The application is based on extensive, long-term safety and efficacy data, which is crucial for regulators, clinicians, and …

Trading Systems Reacting to (BMRN) Volatility

This article analyzes Biomarin Pharmaceutical Inc. (NASDAQ: BMRN) volatility, identifying a neutral near-term sentiment with a mid-channel oscillation pattern. It highlights an exceptional short setup with a 25.3:1 risk-reward ratio and outlines three AI-generated trading strategies for different risk profiles: Position Trading, Momentum Breakout, …

2 Reasons to Avoid BMRN and 1 Stock to Buy Instead

BioMarin Pharmaceutical (BMRN) is not recommended due to its stagnant adjusted operating margin and mediocre return on invested capital over the last five years. Despite a reasonable forward P/E, its shaky fundamentals present too much downside risk. The article suggests investing in an entrenched …

BMRN6299744 Bond Risk Profile

This article provides a risk profile for the BioMarin Pharmaceutical Inc. 5.5% 15-FEB-2034 corporate bond, identified as BMRN6299744. It outlines key metrics for credit risk assessment, including security level and issuer rating. The offering also suggests access to exclusive analyst ratings for additional insights.

BMRN6299744 Bond Profile — Key Metrics

This article provides a detailed profile of the BioMarin Pharmaceutical Inc. bond, BMRN6299744, highlighting its key metrics. It includes information such as the issuer, issue and maturity dates, outstanding amount, face value, minimum denomination, and coupon rate. The bond is a 5.5% bond maturing …